Gorji v. C.R. Bard Inc

CourtDistrict Court, D. Nebraska
DecidedFebruary 28, 2022
Docket4:21-cv-03134
StatusUnknown

This text of Gorji v. C.R. Bard Inc (Gorji v. C.R. Bard Inc) is published on Counsel Stack Legal Research, covering District Court, D. Nebraska primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gorji v. C.R. Bard Inc, (D. Neb. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEBRASKA

KYLA GORJI,

Plaintiff, 4:21CV3134

vs. ORDER

C.R. BARD, INC., A Corporation; BARD ACCESS SYSTEMS, INC., A Corporation; and BECTON, DICKINSON AND COMPANY, A Corporation

Defendants.

This matter comes before the Court on Defendants’ Motion to Strike the Amended Complaint’s Prayer for Punitive Damages (Filing No. 22). Defendants move the Court for an order under Rule 12(f) of the Federal Rule of Civil Procedure striking Plaintiff’s request for punitive damages from her Amended Complaint (Filing No. 11). For the following reasons, the Court will grant the motion.

BACKGROUND Plaintiff, a resident of Lincoln, Nebraska, filed the instant action against Defendants seeking damages she claims to have sustained from the placement of a port/catheter system designed, manufactured, marketed, and sold by Defendants. (Filing No. 11). Defendant C.R. Bard, Inc., a New Jersey corporation, and Defendant Bard Access Systems, Inc. (“BAS”), a Utah corporation, are wholly owned subsidiaries of Defendant Becton Dickinson and Company, a New Jersey corporation. (Filing No. 11 at pp. 1-2; Filing No. 24 at pp. 1-2). Defendants are engaged in the business of researching, developing, designing, licensing, manufacturing, distributing, supplying, selling, marketing, and introducing into interstate commerce medical devices, including the device at issue, the Bard PowerPort isp M.R.I. Implantable Port (“PowerPort”). (Filing No. 11 at pp. 1-2). Defendants conduct substantial business in Nebraska, and BAS distributes vascular access products in Nebraska. (Filing No. 24 at p. 2). The PowerPort is an implantable vascular access device designed to allow repeated access to a patient’s vascular system for administration of medication, intravenous fluids, parenteral nutrition solutions, and blood products. (Filing No. 11 at p. 3). The PowerPort is used in treating cancer patients receiving chemotherapy or rheumatoid arthritis patients requiring long-term medication infusions. (Filing No. 11 at p. 4). On October 1, 2019, Plaintiff underwent placement of the PowerPort. On October 17, 2019, after it was discovered the PowerPort had fractured and the tip had migrated into Plaintiff’s heart, she underwent a fluoroscopically guided retrieval of the fractured tip and catheter at Bryan Medical Center West in Lincoln, Nebraska. The next day while still at Bryan Medical Center, Plaintiff underwent removal of the PowerPort and a new device from a different manufacturer was implanted in her right jugular. (Filing No. 11 at p. 8). Plaintiff alleges Defendants obtained clearance to market the PowerPort pursuant to § 510(k) of the Medical Device Amendments (“MDA”) to the Food, Drug, and Cosmetic Act (“FDCA”). Section 501(k) allows a manufacturer to market a medical device that is substantially equivalent to other legally marketed predicate devices without a formal safety or efficacy review. Once a product is cleared under § 510(k), the manufacturer has a continuing obligation to investigate and report any adverse events associated with the device and must periodically submit any new information to the Food and Drug Administration (“FDA”) that may affect its previous safety and efficacy conclusion. (Filing No. 11 at pp. 4-5). Plaintiff then alleges that after the PowerPort was put on the market, Defendants received several adverse event reports from healthcare providers, including reports the PowerPort was fracturing, migrating, and otherwise malfunctioning after implantation, causing perforations of internal vasculature, and resulting in patient injuries such as hemorrhage, cardiac tamponade or arrhythmias, and persistent pain. (Filing No. 11 at p. 6). Plaintiff further alleges as follows: Defendants submitted thousands of device adverse event reports to the Alternative Summary Reporting (“ASR”) program which, according to the Plaintiff, was a controversial reporting system that effectively concealed reported PowerPort failures from medical professionals and patients; the FDA halted the ASR program in 2019 after a multipart investigative journalism piece published in a prominent health news publication prompted widespread outcry from medical professionals and patient advocacy groups; (Filing No. 11 at p. 6); Defendants intentionally concealed the severity of complications caused by the PowerPort device and the likelihood of such events occurring in the future by failing to submit the adverse event reports it received to the publicly available Manufacturer and User Facility Device Experience (“MAUDE”) database; (Filing No. 11 at p. 7); and rather than alter the design of the PowerPort or adequately warn physicians of its danger, Defendants “continued to actively and aggressively market the PowerPort as safe,” despite their knowledge of numerous reports of catheter fracture and migration. Plaintiff asserts Defendants’ conduct “constitutes willful, wanton, gross, and outrageous corporate conduct that demonstrates a conscious disregard for the safety of Plaintiff.” (Filing No. 11 at p. 7). Plaintiff’s prayer for relief seeks several types of damages for her injuries, including punitive damages. (Filing No. 11 at p. 22). Defendants initially asked the Court to dismiss Plaintiff’s prayer for punitive damages in their motion to dismiss filed under Rule 12(b)(6). (Filing No. 13 at p. 1). The Court denied Defendants’ request because “Rule 12(b)(6) functions to dismiss claims—not prayers for relief.” The Court stated it would consider a motion to strike the prayer for punitive damages at the appropriate time. (Filing No. 21 at p. 10). That is the matter now before the Court. Defendants move to strike Plaintiff’s prayer for punitive damages because punitive damages are prohibited under Nebraska law. (Filing No. 23 at p. 2). Plaintiff opposes the motion and contends there is a true conflict of laws in this case with respect to punitive damages. Plaintiff argues that under Nebraska’s “most significant relationship” choice-of-law rules, New Jersey or Utah has a more significant interest in punishing willfully bad actors incorporated in their states. (Filing No. 27 at pp. 3-5). Plaintiff also argues that Defendants’ Motion to Strike is premature as no discovery has taken place and it is unclear at this point whether such punitive damages are appropriate. (Filing No. 27 at p. 2).

ANALYSIS Defendants first argue Plaintiff has waived her choice-of-law argument by failing to raise it in response to Defendants’ Rule 12(b)(6) motion to dismiss Plaintiff’s prayer for punitive damages. (Filing No. 28 at pp. 1-2). However, as Judge Gerrard stated in his Memorandum and Order, “Rule 12(b)(6) functions to dismiss claims—not prayers for relief,” and specifically recognized the punitive damages issue is more appropriately considered on a motion to strike under Rule 12(f). As such, Plaintiff’s failure to raise a choice-of-law argument in response to Defendants’ improper motion to dismiss Plaintiff’s prayer for punitive damages did not result in a waiver of that argument. Rule 12(f) of the Federal Rules of Civil Procedure permits courts to “strike from a pleading an insufficient defense or any redundant, immaterial, impertinent, or scandalous matter.” Fed. R. Civ. P. 12(f). “Judges enjoy liberal discretion to strike pleadings under Rule 12(f).” BJC Health Sys. v. Columbia Cas. Co., 478 F.3d 908, 917 (8th Cir. 2007) (citing Nationwide Ins. Co. v. Cent. Mo. Elec.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Gorji v. C.R. Bard Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gorji-v-cr-bard-inc-ned-2022.